Cadila Healthcare is currently trading at Rs. 863.55, up by 6.10 points or 0.71 % from its previous closing of Rs. 857.45 on the BSE.
The scrip opened at Rs. 862.00 and has touched a high and low of Rs. 877.00 and Rs. 853.00 respectively. So far 11409 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 924.60 on 22-Feb-2013 and a 52 week low of Rs 631.00 on 20-Aug-2013.
Last one week high and low of the scrip stood at Rs 908.00 and Rs 849.40 respectively. The current market cap of the company is Rs 17712.79 crore.
The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 13.80% and 11.41% respectively.
Zydus Cadila has received the final approval from the United States Food and Drugs Administration (USFDA) to Bupropion Hydrochloride Extended-release Tablets USP (XL) in the strength of 300 mg. The drug falls in the anti-depressants segment. The estimated sales in 2013 as per IMS for Bupropion Hydrochloride Extended-release Tablets USP (XL), 300 mg were $255.9 million. The total market for Bupropion was estimated at $526.7 million. The group now has 87 approvals and has so far filed 216 ANDAs since the commencement of filing process in FY 2003-04.
Cadila Healthcare, the flagship company of Zydus Cadila Group, focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: